Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group
Objective Patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD) are
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group
D Khanna, C Tseng, N Farmani, V Steen, DE Furst… - 2011 - deepblue.lib.umich.edu
Objective Patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD) are
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group
D Khanna, CH Tseng, N Farmani, V Steen… - Arthritis & …, 2011 - Wiley Online Library
Objective Patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD) are
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
[PDF][PDF] Clinical Course of Lung Physiology in Patients with Scleroderma and Interstitial Lung Disease: Analysis of the Scleroderma Lung Study Placebo Group
D Khanna, CH Tseng, N Farmani, V Steen, DE Furst… - Arthritis …, 2011 - academia.edu
Background—Patients with scleroderma interstitial lung disease (SSc-ILD) are thought to
have the greatest decline in lung function (forced vital capacity% predicted [FVC%]) in the …
have the greatest decline in lung function (forced vital capacity% predicted [FVC%]) in the …
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group.
D Khanna, CH Tseng, N Farmani, V Steen… - Arthritis and …, 2011 - europepmc.org
Objective Patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) are
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
[HTML][HTML] Clinical Course of Lung Physiology in Patients with Scleroderma and Interstitial Lung Disease: Analysis of the Scleroderma Lung Study Placebo Group
D Khanna, CH Tseng, N Farmani, V Steen… - Arthritis and …, 2011 - ncbi.nlm.nih.gov
Background Patients with scleroderma interstitial lung disease (SSc-ILD) are thought to
have the greatest decline in lung function (forced vital capacity% predicted [FVC%]) in the …
have the greatest decline in lung function (forced vital capacity% predicted [FVC%]) in the …
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group
D Khanna, CH Tseng, N Farmani, V Steen… - Arthritis & …, 2011 - infona.pl
Objective Patients with systemic sclerosis–associated interstitial lung disease (SSc‐ILD) are
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
[引用][C] Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: Analysis of the Scleroderma Lung Study Placebo Group
D Khanna, CH Tseng, N Farmani, V Steen… - Arthritis & …, 2011 - cir.nii.ac.jp
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease:
Analysis of the Scleroderma Lung Study Placebo Group | CiNii Research CiNii 国立情報学 …
Analysis of the Scleroderma Lung Study Placebo Group | CiNii Research CiNii 国立情報学 …
[PDF][PDF] Clinical Course of Lung Physiology in Patients With Scleroderma and Interstitial Lung Disease
D Khanna, CH Tseng, N Farmani, V Steen… - ARTHRITIS & …, 2011 - Citeseer
Methods. Patients randomized to receive placebo (n 79) were divided into 3 groups based
on the duration of SSc (0–2 years, 2–4 years, and> 4 years). Descriptive statistics and a …
on the duration of SSc (0–2 years, 2–4 years, and> 4 years). Descriptive statistics and a …
Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group
D Khanna, CH Tseng, N Farmani, V Steen, DE Furst… - 2011 - pubmed.ncbi.nlm.nih.gov
Objective Patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) are
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …
thought to have the greatest decline in lung function (forced vital capacity [FVC]% predicted) …